Drug Type Antibody drug conjugate (ADC) |
Synonyms |
Target |
Mechanism IL-13Rα2 inhibitors(Interleukin-13 receptor subunit alpha-2 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC39H67N5O7 |
InChIKeyDASWEROEPLKSEI-UIJRFTGLSA-N |
CAS Registry474645-27-7 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neoplasms | Preclinical | CN | 04 Apr 2023 | |
Solid tumor | Preclinical | CN | 09 May 2022 |